Promising research trials surrounding the medication Retatrutide , specifically the high-dose formulation referred to as ZPHC, reveal a significant effect on body mass decrease and related chronic factors. Researchers anticipate that this dual agonist , targeting both GLP-1 and GIP systems, has the potential to represent a major breakthrough in th